STOCK TITAN

[Form 4] CHEMED CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Chemed Corp (CHE) reported a Form 4 for VP & Chief Financial Officer Michael D. Witzeman, showing a grant of 19,486 stock options on 10/21/2025. Each option has an exercise price of $443.79 and is a right to buy capital stock, expiring on 10/21/2030.

The award vests in three equal annual installments commencing 10/21/2026. Following this transaction, the reporting person beneficially owned 53,970 derivative securities, held in Direct ownership form.

Chemed Corp (CHE) ha riferito un Modulo 4 per il vicepresidente e chief financial officer Michael D. Witzeman, indicando un grant di 19,486 stock options il 21/10/2025. Ogni opzione ha un prezzo di esercizio di $443.79 ed è un diritto all'acquisto di azioni, con scadenza al 21/10/2030.

L'assegnazione matura in tre rate annuali uguali a partire dal 21/10/2026. A seguito di questa operazione, la persona che riferisce deteneva beneficiariamente 53.970 strumenti derivati, detenuti in forma di proprietà Direct.

Chemed Corp (CHE) reportó un Form 4 para el VP y director financiero Michael D. Witzeman, mostrando una asignación de 19,486 opciones sobre acciones el 21/10/2025. Cada opción tiene un precio de ejercicio de $443.79 y es un derecho para comprar acciones de capital, con vencimiento el 21/10/2030.

La adjudicación se consolida en tres cuotas anuales iguales que comienzan el 21/10/2026. Tras esta operación, la persona que informa poseía beneficiosamente 53,970 valores derivados, mantenidos en forma de propiedad Directa.

Chemed Corp (CHE)가 부사장 겸 최고재무책임자 Michael D. Witzeman를 위한 Form 4를 보고했으며 2025/10/2119,486 주식옵션이 부여되었다고 표시합니다. 각 옵션의 행사 가격은 $443.79이고 자본주식 매입 권리이며 만료일은 2030/10/21입니다.

수여는 2026/10/21부터 시작되는 동일한 연간 3회 분할로 속하며, 이 거래 이후 보고자는 53,970 파생증권직접 소유 형태로 보유하고 있습니다.

Chemed Corp (CHE) a déclaré un Form 4 pour le vice-président exécutif et directeur financier Michael D. Witzeman, indiquant une attribution de 19 486 options d'achat d'actions le 21/10/2025. Chaque option a un prix d'exercice de $443.79 et constitue un droit d'acheter des actions ordinaires, expirant le 21/10/2030.

L'attribution vest en trois versements annuels égaux à partir du 21/10/2026. Suite à cette transaction, la personne déclarant détenait avantageusement 53 970 dérivés, détenus sous forme de propriété Directe.

Chemed Corp (CHE) meldete ein Formular 4 für VP & Chief Financial Officer Michael D. Witzeman, das eine Gewährung von 19,486 Aktienoptionen zum 21.10.2025 zeigt. Jede Option hat einen Ausübungspreis von $443.79 und ist ein Recht zum Kauf von Kapitalaktien, mit Ablauf am 21.10.2030.

Die Zuteilung erfolgt in drei gleichen jährlichen Raten beginnend am 21.10.2026. Nach dieser Transaktion besaß die meldende Person vorteilhaft 53.970 Derivatewerte, gehalten in Form von Direct Eigentum.

Chemed Corp (CHE) أبلغت عن نموذج 4 للنائب الأول للرئيس والمدير الماليMichael D. Witzeman، مع إظهار منح 19,486 خيار أسهم في 21/10/2025. كل خيار له سعر ممارسة قدره $443.79، وهو حق لشراء أسهم رأس المال، منتهي الصلاحية في 21/10/2030.

يتوزع المنح على ثلاث دفعات سنوية متساوية تبدأ من 21/10/2026. عقب هذه المعاملة، امتلك الشخص المبلغ عنه بصورة مستفيدة 53,970 أداة مشتقة، محفوظة في صيغة ملكية Direct.

Positive
  • None.
Negative
  • None.

Chemed Corp (CHE) ha riferito un Modulo 4 per il vicepresidente e chief financial officer Michael D. Witzeman, indicando un grant di 19,486 stock options il 21/10/2025. Ogni opzione ha un prezzo di esercizio di $443.79 ed è un diritto all'acquisto di azioni, con scadenza al 21/10/2030.

L'assegnazione matura in tre rate annuali uguali a partire dal 21/10/2026. A seguito di questa operazione, la persona che riferisce deteneva beneficiariamente 53.970 strumenti derivati, detenuti in forma di proprietà Direct.

Chemed Corp (CHE) reportó un Form 4 para el VP y director financiero Michael D. Witzeman, mostrando una asignación de 19,486 opciones sobre acciones el 21/10/2025. Cada opción tiene un precio de ejercicio de $443.79 y es un derecho para comprar acciones de capital, con vencimiento el 21/10/2030.

La adjudicación se consolida en tres cuotas anuales iguales que comienzan el 21/10/2026. Tras esta operación, la persona que informa poseía beneficiosamente 53,970 valores derivados, mantenidos en forma de propiedad Directa.

Chemed Corp (CHE)가 부사장 겸 최고재무책임자 Michael D. Witzeman를 위한 Form 4를 보고했으며 2025/10/2119,486 주식옵션이 부여되었다고 표시합니다. 각 옵션의 행사 가격은 $443.79이고 자본주식 매입 권리이며 만료일은 2030/10/21입니다.

수여는 2026/10/21부터 시작되는 동일한 연간 3회 분할로 속하며, 이 거래 이후 보고자는 53,970 파생증권직접 소유 형태로 보유하고 있습니다.

Chemed Corp (CHE) a déclaré un Form 4 pour le vice-président exécutif et directeur financier Michael D. Witzeman, indiquant une attribution de 19 486 options d'achat d'actions le 21/10/2025. Chaque option a un prix d'exercice de $443.79 et constitue un droit d'acheter des actions ordinaires, expirant le 21/10/2030.

L'attribution vest en trois versements annuels égaux à partir du 21/10/2026. Suite à cette transaction, la personne déclarant détenait avantageusement 53 970 dérivés, détenus sous forme de propriété Directe.

Chemed Corp (CHE) meldete ein Formular 4 für VP & Chief Financial Officer Michael D. Witzeman, das eine Gewährung von 19,486 Aktienoptionen zum 21.10.2025 zeigt. Jede Option hat einen Ausübungspreis von $443.79 und ist ein Recht zum Kauf von Kapitalaktien, mit Ablauf am 21.10.2030.

Die Zuteilung erfolgt in drei gleichen jährlichen Raten beginnend am 21.10.2026. Nach dieser Transaktion besaß die meldende Person vorteilhaft 53.970 Derivatewerte, gehalten in Form von Direct Eigentum.

Chemed Corp (CHE) أبلغت عن نموذج 4 للنائب الأول للرئيس والمدير الماليMichael D. Witzeman، مع إظهار منح 19,486 خيار أسهم في 21/10/2025. كل خيار له سعر ممارسة قدره $443.79، وهو حق لشراء أسهم رأس المال، منتهي الصلاحية في 21/10/2030.

يتوزع المنح على ثلاث دفعات سنوية متساوية تبدأ من 21/10/2026. عقب هذه المعاملة، امتلك الشخص المبلغ عنه بصورة مستفيدة 53,970 أداة مشتقة، محفوظة في صيغة ملكية Direct.

Chemed Corp (CHE) 报告了为副总裁兼首席财务官 Michael D. Witzeman 的 Form 4,显示于 2025/10/21 授予 19,486 股票期权。每个期权的行使价为 $443.79,是购买普通股的权利,期限至 2030/10/21

该授予在三个等额年度分期归属,从 2026/10/21 开始。此交易后,申报人实际拥有 53,970 衍生证券,以 直接 所有形式持有。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Witzeman Michael D

(Last) (First) (Middle)
2600 CHEMED CENTER
255 EAST FIFTH STREET

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHEMED CORP [ CHE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP & Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy with tandem tax withholding) $443.79 10/21/2025 A 19,486 (1) 10/21/2030 Capital Stock 19,486 $443.79 53,970 D
Explanation of Responses:
1. Vesting in three equal annual installments commencing 10/21/2026
Michael D. Witzeman 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CHE disclose in this Form 4?

A grant of 19,486 stock options to the VP & CFO, Michael D. Witzeman, on 10/21/2025 at an exercise price of $443.79.

How many options were granted and at what exercise price for CHE?

19,486 stock options with an exercise price of $443.79 per share.

What is the vesting schedule for the CHE CFO’s options?

Vesting occurs in three equal annual installments commencing 10/21/2026.

When do the reported CHE options expire?

The options expire on 10/21/2030.

How many derivative securities does the filer own after the transaction?

The reporting person beneficially owned 53,970 derivative securities following the transaction.

What is the ownership form of the reported securities?

The securities are held in Direct ownership form.

Who is the reporting person in CHE’s Form 4?

Michael D. Witzeman, VP & Chief Financial Officer of Chemed Corp.
Chemed Corp

NYSE:CHE

CHE Rankings

CHE Latest News

CHE Latest SEC Filings

CHE Stock Data

6.34B
14.29M
1.98%
97.98%
2.82%
Medical Care Facilities
Services-home Health Care Services
Link
United States
CINCINNATI